May 1st Week, 2025 Regulatory Events   🎯  Summit Therapeutics, Inc.  and  Akeso Biopharma ’s ivonescimab (PD-1 x VEGF BsAb) mono has...

April 1st Week, 2025 Regulatory Events 🎯  AstraZeneca 's neoadjuvant durvalumab (anti-PD-L1) + chemo followed by adjuvant durvalumab...

March 4th Week, 2025 Regulatory Events 🎯  CStone Pharmaceuticals  submitted a Type II variation application to the EMA for sugemalimab...

March 2nd Week, 2025 Mergers & Acquisitions 🤝  Checkpoint Therapeutics Inc  is set to be acquired by  SUN PHARMA , an Indian pharma...

February 4th Week, 2025 📝  Merck  & Co/  MSD 's sBLA for neoadjuvant pembro followed by adjuvant pembro + RT ± cisplatin in resectable,...

February 3rd Week, 2025 📝With the Ph3 CHECKMATE-816 trial meeting its key secondary endpoint of OS, BMS’ nivo + platinum-doublet CT...

April 2nd April, 2025 ⭐ Regulatory Events 🎯 The US FDA cleared an IND application of  CERo Therapeutics, Inc. ’s CER-1236 (anti-Tim-4L...

Highlights from the CHMP March 2025 Meeting are out!  ⭐ Indication Expansions :  💊  Pfizer 's bosutinib (Bosulif; second-generation...

Highlights from the CHMP Feb 2025 Meeting are out! Here are the positive recommendations in the Oncology space: ⭐ New Therapies: 👉...

Welcome to the April edition of our CGT Watch newsletter!   Autolus’ Aucatzyl’s UK approval; BrainChild Bio’s BCB-276 BTD; Lyell’s LYL314...

15/05/2025 Another TIGIT agent fails as iTeos and GSK terminate the belrestotug development program based on disappointing NSCLC and...

24/04/2025 Ivonescimab Plus Chemotherapy Shows Statistically Significant Superiority Over Tislelizumab in First-Line Treatment of...